260413-62-5
Chemical Structure
Ligustroflavone
Synonym(s): Nuezhenoside
- CAS No.: 260413-62-5
- Formula:C33H40O18
- Molecular Weight:724.66
IUPAC Name: 7-(((2S,3R,4S,5S,6R)-4,5-dihydroxy-3-(((2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6-((((2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)-5-hydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one
InChIKey: NULBHTHMVOCGOE-ZBCCAYPVSA-N
SMILES: O=C(C=C(C1=CC=C(O)C=C1)OC2=CC(O[C@H](O[C@H](CO[C@H](O[C@@H](C)[C@H](O)[C@H]3O)[C@@H]3O)[C@@H](O)[C@@H]4O)[C@@H]4O[C@@](O[C@@H](C)[C@H](O)[C@H]5O)([H])[C@@H]5O)=C6)C2=C6O
Biological Activity: Ligustroflavone is an orally active flavonoid compound. Ligustroflavone can be extracted from Ligustrum lucidum. Ligustroflavone antagonizes the calcium-sensing receptor (CaSR), inhibits the RIPK1/RIPK3/MLKL pathway, and downregulates TGF-β/Smad signaling. Ligustroflavone regulates calcium metabolism, protects bone tissue, reduces cerebral ischemic injury, and inhibits liver fibrosis. Ligustroflavone can be used in the study of diabetic osteoporosis, ischemic stroke, and liver fibrosis[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Ligustroflavone | 99.90% | Ligustroflavone is an orally active flavonoid compound. Ligustroflavone can be extracted from Ligustrum lucidum. Ligustroflavone antagonizes the calcium-sensing receptor (CaSR), inhibits the RIPK1/RIPK3/MLKL pathway, and downregulates TGF-β/Smad signaling. Ligustroflavone regulates calcium metabolism, protects bone tissue, reduces cerebral ischemic injury, and inhibits liver fibrosis. Ligustroflavone can be used in the study of diabetic osteoporosis, ischemic stroke, and liver fibrosis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Ligustroflavone (Standard) | ≥98% | Ligustroflavone (Standard) is the analytical standard of Ligustroflavone (HY-N0546). This product is intended for research and analytical applications. Ligustroflavone is an orally active flavonoid compound. Ligustroflavone can be extracted from Ligustrum lucidum. Ligustroflavone antagonizes the calcium-sensing receptor (CaSR), inhibits the RIPK1/RIPK3/MLKL pathway, and downregulates TGF-β/Smad signaling. Ligustroflavone regulates calcium metabolism, protects bone tissue, reduces cerebral ischemic injury, and inhibits liver fibrosis. Ligustroflavone can be used in the study of diabetic osteoporosis, ischemic stroke, and liver fibrosis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Feng R, et al. Protective Effects of Ligustroflavone, an Active Compound from Ligustrum lucidum, on Diabetes-Induced Osteoporosis in Mice: A Potential Candidate as Calcium-Sensing Receptor Antagonist. Am J Chin Med. 2019;47(2):457-476. [Content Brief]
- [2]. Zhang YY, et al. Ligustroflavone reduces necroptosis in rat brain after ischemic stroke through targeting RIPK1/RIPK3/MLKL pathway. Naunyn Schmiedebergs Arch Pharmacol. 2019 Sep;392(9):1085-1095. [Content Brief]
- [3]. Kang R, et al. Ligustroflavone ameliorates CCl4-induced liver fibrosis through down-regulating the TGF-β/Smad signaling pathway. Chin J Nat Med. 2021 Mar;19(3):170-180. [Content Brief]
